OncoCyte Co. (NYSEAMERICAN:OCX) Receives Consensus Recommendation of Buy from Analysts

Shares of OncoCyte Co. (NYSEAMERICAN:OCX – Get Rating) have been given an average rating of “Buy” by the six analysts that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target […]

Related Keywords

United States ,Ronald Asbury Andrews ,Piper Sandler ,Oncocyte Co ,Zacks Investment Research ,Blackrock Inc ,Capital Partners ,Needham Company ,Oncocyte Corporation ,Oncocyte Company Profile Get Rating ,Defender Capital ,Broadwood Capital Inc ,Dimensional Fund Advisors ,Get Rating ,Lake Street Capital ,Investment Research ,Broadwood Partners ,Asbury Andrews ,Fund Advisors ,Cyte Company Profile ,Cyte Corporation ,Oncocyte ,Nyseamerican Ocx ,Socx ,Medical ,Ratings ,Consensus ,